Shares of Intensity Therapeutics, Inc. (INTS) are up 142% on Friday after the company announced positive Phase 2 INVINCIBLE trial data of INT230-6 in patients with early-stage breast cancer without chemotherapy.
INTS is trading on the Nasdaq at $10.18, up 142.38% or $5.98 per share. It has traded between $2.01 and $11.09 in the past 52-week period.
The INVINCIBLE Trial was a randomized Phase 2 study that involved women with newly diagnosed, operable early-stage intermediate or high-grade T1-T2 invasive breast cancers.
The trial data revealed that INT230-6 has a favorable safety profile and is well-tolerated. Over 95% of the treatment-emergent adverse events (TEAEs) reported were low-grade 1 or 2 primarily localized pain, fatigue, and nausea.
It was also found that a single injection of INT230-6 could induce up to >95% necrosis of a tumor.
Angel Arnaout, M.D., MSc., who is a Professor of Surgery at the University of Ottawa and Co-Lead of the Ontario Institute for Cancer Research's Window-of-Opportunity Network, stated that the ability of INT230-6 to induce necrosis and immune effects before a patient's surgery, while maintaining a safe profile, would be a significant step forward for the treatment of breast cancer and potentially other cancers as well.
This data was presented during the 2023 San Antonio Breast Cancer Symposium (SABCS) in a Podium Poster Spotlight discussion session.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.